Johnson & Johnson (JNJ)vsOPTIMIZERx Corp (OPRX)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
OPRX
OPTIMIZERx Corp
$6.23
+1.47%
HEALTHCARE · Cap: $120.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 87959% more annual revenue ($96.36B vs $109.43M). JNJ leads profitability with a 21.8% profit margin vs 4.7%. OPRX appears more attractively valued with a PEG of 1.61. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
OPRX
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for OPRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 27.7%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 4.2% — below average capital efficiency
4.7% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : OPRX
The strongest argument for OPRX centers on Price/Book, Operating Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : OPRX
The primary concerns for OPRX are PEG Ratio, Market Cap, Return on Equity. Thin 4.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while OPRX is a value play — different risk/reward profiles.
OPRX carries more volatility with a beta of 1.28 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 49/100), backed by strong 21.8% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →OPTIMIZERx Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
OptimizeRx Corporation is a digital health company providing communications solutions for life sciences companies, physicians, and patients. The company is headquartered in Rochester, Michigan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?